Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 10/20 | 0.39 |
| ▸ | TTR | P02766 | 5/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | DKK1 | O94907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345098 | 0.80 | SCD (0.35) | RBP4 | |
| SCHEMBL345182 | 0.77 | CHRM4 (0.45) | RBP4TTRGPBAR1KDM4EACACB | |
| SCHEMBL344848 | 0.74 | ACACB (0.38) | RBP4ACACB | |
| SCHEMBL345166 | 0.72 | CHRM4 (0.43) | RBP4TTRGPBAR1KDM4EACACB | |
| SCHEMBL345643 | 0.70 | HDAC6 (0.38) | KDM4EACACB | |
| SCHEMBL9993658 | 0.70 | HRH3 (0.38) | ACACB | |
| SCHEMBL2329427 | 0.70 | GPBAR1 (0.44) | RBP4TTRPANK3GPBAR1KDM4E | |
| Hydrochloric Acid SCHEMBL345732 | 0.70 | SMYD3 (0.38) | — | |
| SCHEMBL345792 | 0.69 | PKM (0.36) | RBP4KDM4E | |
| SCHEMBL345630 | 0.69 | PKM (0.36) | KDM4EACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | RBP4 2582/4885TTR 1490/4885SCN9A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.